Grant: CIHR Fellowship
McMaster University
$135,000.00
Age-associated inflammation alters myeloid cell development and function
EF 2019-20
Résumé
Recent statistics tell us that 90 percent of Canadians aged 65 and over live with at least one chronic condition including heart disease, respiratory conditions, diabetes, or arthritis. While the cause of chronic disease is complex and multifactorial, age-related changes to the immune system are a major contributor. Stem cells in the bone marrow give rise to two different lineages of immune cells: myeloid and lymphoid immune cells. As people age, these stem cells may acquire genetic mutations that skew the differentiation of immune cells towards the myeloid lineage at the expense of lymphoid cells. In addition to this "myeloid-skewing", the immune cells are often immature and have reduced function. Accumulating evidence suggests that this predisposes older adults to developing health complications, but the genetic changes that occur in the stem cells and the molecular events that underlie these changes remain unclear.
The aim of my postdoctoral fellows is to determine the link between myeloid genetic mutations, myeloid-skewing, and immune impairment with age. We hypothesize that mutations in a specific gene called TET2 results in myeloid impairment. This is thought to be driven by the aging bone marrow environment, which has increased inflammatory mediators.
To approach this, I will integrate my prior experience in machine learning with a custom next-generation sequencing platform to identify genetic biomarkers in blood of elderly patients. Concurrently, I will use transplantation studies in Tet2 knockout mice to determine if inflammatory mediators in the aging bone marrow results in myeloid-skewing and impairment.
These experiments will determine whether modifying inflammatory mediators in the bone marrow is a viable option for reducing myeloid skewing, which we can pursue in subsequent experiments by administering inflammatory blockers. Ultimately, we believe the results of this research will provide avenues for new therapeutic interventions.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
412787
Name
Quin Candice S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Age-associated inflammation alters myeloid cell development and function
Programtype2
Fellowship Programs
Orgnameinp2
McMaster University
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Aging; Geroscience; Inflammation; Myelopoiesis
Abstract
Recent statistics tell us that 90 percent of Canadians aged 65 and over live with at least one chronic condition including heart disease, respiratory conditions, diabetes, or arthritis. While the cause of chronic disease is complex and multifactorial, age-related changes to the immune system are a major contributor. Stem cells in the bone marrow give rise to two different lineages of immune cells: myeloid and lymphoid immune cells. As people age, these stem cells may acquire genetic mutations that skew the differentiation of immune cells towards the myeloid lineage at the expense of lymphoid cells. In addition to this "myeloid-skewing", the immune cells are often immature and have reduced function. Accumulating evidence suggests that this predisposes older adults to developing health complications, but the genetic changes that occur in the stem cells and the molecular events that underlie these changes remain unclear.
The aim of my postdoctoral fellows is to determine the link between myeloid genetic mutations, myeloid-skewing, and immune impairment with age. We hypothesize that mutations in a specific gene called TET2 results in myeloid impairment. This is thought to be driven by the aging bone marrow environment, which has increased inflammatory mediators.
To approach this, I will integrate my prior experience in machine learning with a custom next-generation sequencing platform to identify genetic biomarkers in blood of elderly patients. Concurrently, I will use transplantation studies in Tet2 knockout mice to determine if inflammatory mediators in the aging bone marrow results in myeloid-skewing and impairment.
These experiments will determine whether modifying inflammatory mediators in the bone marrow is a viable option for reducing myeloid skewing, which we can pursue in subsequent experiments by administering inflammatory blockers. Ultimately, we believe the results of this research will provide avenues for new therapeutic interventions.
Competitiondate
201910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Quin, Candice S
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~